GeoVax Labs, Inc. is a biopharmaceutical company developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections. Its goal is to develop an AIDS vaccine for use globally.
The company announced today that it received a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development Grant supporting GeoVax’s HIV/AIDS vaccine program. Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive this award. GeoVax first received this government award back in 2007.
The most recent award represents the fifth year it has received an award, bringing the total awarded to date to $19.6 million. GeoVax plans to use this additional funding to further production of its GM-CSF adjuvanted vaccine for planned human clinical trials.
Depending on FDA submission schedules, GeoVax anticipates commencing a Phase 1 clinical trial for its vaccine within six months. The company is anxious to begin. Without the adjuvant, its vaccine has already been demonstrated to successfully control infection. With the addition of the adjuvant, GeoVax hopes to actually prevent infection.
For further information on GeoVax and its vaccine, please visit its website at www.geovax.com
Let us hear your thoughts below: